The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
However, in my estimation, starting in 2026, this financial metric will resume growth, including due to Cobenfy, which was ...
Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m. See why I think selling AXSM stock on any ...
However, this came as good news for investors in AbbVie’s peer Bristol Myers Squibb (NYSE:BMY) as the company recently secured the U.S. FDA approval for its schizophrenia drug Cobenfy ...
THURSDAY, Nov. 14, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of ...
Bristol-Myers Squibb has also been making strides in clinical trials. Notably, the FDA approved Cobenfy, a new treatment for schizophrenia, and the company reported promising news about milvexian.
Bristol-Myers Squibb has also been making strides in clinical trials. Notably, the FDA approved Cobenfy, a new treatment for schizophrenia, and the company reported promising news about milvexian.